Kornimate/medical-research-clean huggingface dataset:
randomized clinical and radiographic study

Conditions: Autogenous Dentin Graft

Summary: randomized clinical and radiographic trial

evaluation of autogenous dentin graft versus demineralized freeze-dried bone allograft in the treatment of class ιι and ιιι mandibular furcation defects

Eligibility criteria:
inclusion criteria: - presence of class ii and/or ιιι furcation defects in mandibular first or second molars according to criteria outlined by hamp et. al. 1975. * horizontal probing depth ≥3 mm using naber's probe. * clinical attachment level ≥3 mm measured from cemento-enamel junction (cej) till the deepest probing depth. * evidence of radiolucency in the furcation area on panoramic radiograph. * patients who will be assigned for groups (i and ii) should present with teeth required for extraction due to advanced periodontal bone loss or other indications such as hopeless wisdom teeth or orthodontic indications or unrestorable fractured teeth as a source for autogenous dentin graft (adg). exclusion criteria: * medically compromised patients and systemic conditions precluding periodontal surgery. * mandibular first or second molars with root caries or endodontic treatment. * smokers, diabetics, pregnant or lactating women. * history of chemotherapy, radiotherapy in head and/or neck region. * bisphosphonate therapy.

Keywords: dentin graft, tooth graft
reduced intensity allotransplant for osteopetrosis

Conditions: Osteopetrosis

Summary: we believe that hematopoietic stem cell transplantation (hsct) will help subjects with osteopetrosis generate functioning osteoclasts, and by so doing assist in the resolution of the abnormal bone architecture, and the anemia and bone marrow failure that is also characteristic of this disease. however, we have found in past studies that approximately 30% of osteopetrosis patients do not engraft. therefore, in this study, we plan to use a different combination of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors. the purpose of this research is to find a safer and more effective means of performing stem cell transplantation in patients with osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality.

this transplant protocol will test the following: 1) the ability to achieve engraftment with the reduced intensity protocol, 2) the mortality associated with transplant by day 100, 3) patient outcomes, based on differential imaging and biologic evaluations prior to transplantation and at designated points after transplantation (day 100, 6 months, 1, 2 and 5 years). additional biologic studies will include microarray analysis, campath levels just prior to the administration of the graft, and establishment of mesenchymal stem cell lines. in older patients, studies to evaluation osteoclast differentiation and function will also be offered.

Eligibility criteria:
inclusion criteria: * patients eligible for transplantation under this protocol will be \<45 years of age, and will be diagnosed with severe osteopetrosis. this will be defined as having the following manifestations of the disease. * bones that are uniformly markedly dense based on skeletal survey * no history that would suggest autosomal dominant inheritance * evidence of hematologic changes that are attributed to the underlying disease, including the need for ongoing transfusions, or * the presence of progressive anemia or thrombocytopenia, or a white blood cell differential with a predominance of immature forms and evidence of extramedullary hematopoiesis, or * persistence of serious infectious complications that are thought to be due to the abnormal architecture of the bone that are resistant to surgical and medical interventions. exclusion criteria: * patients \>45 years of age * evidence of hepatic failure * pulmonary dysfunction sufficient to substantially increase the risk of transplant * renal dysfunction with glomerular filtration rate (gfr) \<30% of predicted. * cardiac compromise sufficient to substantially increase the risk of transplantation * severe, stable neurologic impairment. * human immunodeficiency virus (hiv) positivity. * pregnant or lactating females

Keywords: osteopetrosis
adding pd-1 inhibitor to neoadjuvant and adjuvant for npc

Conditions: Nasopharyngeal Carcinoma

Summary: this is a randomized clinical trial comparing neoadjuvant and adjuvant pd-1 inhibitor toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy alone in high-risk nasopharyngeal carcinoma


Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma 2. clinical staged as t4 or n3 （according to the 8th ajcc edition） 3. no evidence of distant metastasis (m0) 4. male and no pregnant female 5. ecog (eastern cooperative oncologygroup) scale 0-1 6. wbc ≥ 4×109 /l and plt ≥4×109 /l and hgb ≥90 g/l 7. normal liver function test (alt、ast ≤ 2.5×uln, tbil≤ 2.0×uln) 8. normal renal function test ( creatinine clearance ≥60 ml/min) exclusion criteria: 1. recurrent or distant metastatic disease. 2. history of malignant tumors (except cured basal cell carcinoma or uterine cervical carcinoma in situ) within the last 5 years. 3. history of radiotherapy or chemotherapy. 4. history of immunodeficiency disease 5. history of organ transplantation 6. presence of life-threatening illness 7. uncontrolled hypercalcemia 8. severe uncontrolled medical conditions or active infectious diseases 9. use of large doses of glucocorticoids, anti-cancer monoclonal antibodies, or other immunosuppressive agents within 4 weeks. 10. pregnant or breastfeeding female 11. emotional disturbance or mental illness 12. refusal or inability to sign informed consent
prevalence and consequences of vitamin d deficiency in pregnant women in switzerland

Conditions: Vitamin D Deficiency

Summary: the purpose of this study is to determine the prevalence of vitamin d deficiency among the population of pregnant women receiving prenatal care and giving birth at the investigators' clinic. the further purposes are to identify the population at risk for vitamin d deficiency and to analyse whether vitamin d deficiency is associated with pregnancy complications.


Eligibility criteria:
inclusion criteria: * pregnant women attending prenatal care at our clinic who had a vitamin d blood-testing at admission exclusion criteria: * pregnant women lost to follow-up, birth outside our clinic

Keywords: vitamin d; pregnancy
a study of patients with aids syndrome

Conditions: Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; HIV Infections; Lymphoma, AIDS-Related

Summary: the purpose of this study is to find out why cancers develop in hiv-positive patients. cancer is a leading cause of death in aids patients. common cancers in hiv-infected patients include kaposi's sarcoma (ks) and non-hodgkin's lymphoma (nhl), a cancer of the immune system. risk factors include certain chemicals, viruses, and perhaps even anti-hiv drugs. doctors would like to find out which risk factors are most important and how they relate to cancer in aids patients.

aids-associated malignancy represents a model system for investigations of carcinogenesis. there are few human conditions in which cancer rates are of the magnitude they are in hiv infection. while studies have investigated pre-cancer markers in hiv-infected patients, they have not correlated these markers with tumor samples. this study contributes to understanding oncogenesis of hiv-associated malignancies by establishing a collection of tumors linked with pre-cancer sera and lymphocyte specimens, as well as prospective questionnaire data. at study entry, patients receive a comprehensive physical exam. clinic staff interview the patient to collect data regarding medication history (particularly antiretroviral exposure), diet, occupational history, substance abuse, and sexual practices. this information is used to identify behavioral and environmental factors contributing to oncogenesis. in addition, baseline blood samples are analyzed for hhv-8 and ebv levels, anti-ebv and anti-hhv-8 antibodies, cd23, th2 cytokines, tumor growth factors, chromosomal translocations associated with nhl, and other potential predictors of malignancy. at month 6 and annually thereafter, patient records are abstracted for data on vital status, aids-defining illnesses, medications, and most recent cd4+ t cell and hiv rna levels. at years 1, 2, and 3, patients undergo physical exams and blood tests for malignancy surveillance. any malignancies are biopsied and analyzed for oncogene identification and virology. the medical records of patients who die on study are reviewed to determine the cause of death and to rule out unreported cancer. no treatment is provided by this study.

Eligibility criteria:
inclusion criteria you may be eligible for this trial if you: * are hiv-positive. * have a cd4+ cell count of 200 cells/mm3 or below. * are 18 years of age or older. exclusion criteria you will not be eligible for this trial if you: * are not available for follow-up for at least 3 years.

Keywords: prospective studies sarcoma, kaposi herpesvirus 4, human acquired immunodeficiency syndrome cohort studies risk factors lymphoma, aids-related antibodies, viral lymphoproliferative disorders viral load herpesvirus, kaposi sarcoma-associated translocation (genetics)
special investigation for gist of sunitinib malate (regulatory post marketing commitment plan).

Conditions: Gastrointestinal Stromal Tumors

Summary: the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the lpd (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first sunitinib malate(sutent) should be registered.

Eligibility criteria:
inclusion criteria: patients need to be administered sunitinib malate(sutent) in order to be enrolled in the surveillance. exclusion criteria: patients not administered sunitinib malate(sutent).
intervention to reduce serious mental illness and suicide stigma among medical students

Conditions: Stigmatization; Clinical Competence

Summary: the team aims to develop and test the efficacy of a serious mental illness (smi) and suicide ideation and attempt (sia) stigma reduction intervention for medical students. the team expects that after intervention exposure, relative to control group, participants in the experimental condition will manifest more favorable change in knowledge, attitudes, and behaviors.

people with serious mental illness (psmi; i.e. schizophrenia and bipolar disorder) die, on average, 25 years earlier than the general population. suicide is a key factor for this disparity as it is the leading cause of unnatural deaths among this population. research identifies latinos as a particularly vulnerable group, accounting for one of the highest rates (over 30%) of serious mental illness (smi) among ethnic minorities in the united states (us). latinos also hold one of the highest prevalence of suicide ideation and attempts (sia) with rates of 10.1% and 4.4% respectively. this scenario worsens for one latino subgroup, puerto ricans, who have the highest prevalence of smi (36%) and sia among latinos in the us (7.9% and 3.5% respectively). taken together, these facts present a concerning scenario for latinos, especially puerto ricans with smi/sia. health professionals play a key role in identifying smi/sia among patients; unfortunately, smi/sia stigma hinders this process. the proposed study aims to: 1) develop the content of an intervention to reduce smi/sia stigma among medical students, 2) determine the acceptability and feasibility of implementing the intervention among medical students by examining recruitment/screening procedures, participation/refusal/retention rates, and participant satisfaction, and; 3) pilot test the preliminary efficacy of the intervention in reducing smi/sia stigma among medical students by increasing knowledge of smi and sia, reducing negative attitudes towards smi/sia and increasing behavioral skills for providing healthcare to psmi.

Eligibility criteria:
inclusion criteria: * medical student currently in third year of medical school training exclusion criteria: * do not speak english
probabilistic targeting of the vim

Conditions: Essential Tremor; Deep Brain Stimulation

Summary: after having included the most improved patients by dbs among those implanted in bordeaux hospital university, and having defined the most active plots on tremor by its prospective grading on fahn-tolosa-marin (ftm) scale and accelerometry, coordinates of active plots and landmarks will be calculated on post-operative imaging. association between landmarks and active plots coordinates will be modelled with machine-learning algorithms. the aim is to retrieve the position of the vim on the basis of the landmarks coordinates.

the intermedius ventralis nucleus of the thalamus (vim), which represents the target for deep brain stimulation (dbs) in essential tremor, still remains invisible to imaging in spite of the development of new mr sequences. the coordinates currently used in the classical (acpc) system are so imprecise that per-operative electrophysiology is mandatory to locate the exact position of this target. micro-electrode recordings (mer) however improve hemorrhagic risk and may be poorly tolerated by patients operated on 7 to 8 hours under local anaesthesia. based on litterature review, no one tried to retrieve the position of the vim from anatomical landmarks coordinates in the era of mri. the patients operated will be clinically tested to define those very well improved by the stimulation. stimulation efficacy will be assessed by comparing the clinical evaluation (ftm scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. coordinates of the anatomical landmarks will be calculated on the pre-operative mri and those of the active plots on the fusion between post-operative ct-scan and pre-operative mri. these coordinates will be analysed by machine-learning algorithms to create a model predicting the position of the active contacts from the coordinates of the landmarks.

Eligibility criteria:
inclusion criteria: * patient older than 18 years * who underwent a dbs surgery targeting the vim at bordeaux university hospital * in the strict indication of the essential tremor * with an excellent post-operative result defined by a complete withdrawal of medication, a stability of the stimulation effects without any setting adjustments since at least 3 months and an improvement of more than 66% on the ftm scale between off and on-stimulation assessments. exclusion criteria: - patients who underwent a dbs surgery targeting the vim for different indications (parkinson's disease for instance), patients with a poor post-operative efficacy

Keywords: probabilistic targeting vim-dbs machine-learning essential tremor
an open label study of romiplostim in adult thrombocytopenic subjects with itp

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura

Summary: this protocol will provide open label romiplostim to adult thrombocytopenic subjects. romiplostim will be administered by subcutaneous injection once per week. dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. rescue therapies are allowed at any time during the study. reductions in concurrent itp therapies may occur at any time when platelet counts are \> 50,000.


Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age * subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the american society of hematology guidelines * if subject is \> 60 years of age, subject has a written bone marrow aspiration and/or biopsy report consistent with a diagnosis of itp * subject has received at least 1 prior therapy for itp * subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is uncontrolled with conventional therapies * subject (or legally-acceptable representative) is willing and able to provide written informed consent exclusion criteria: * subject has a history of hematological malignancy, myeloproliferative disorder, myelodysplastic syndrome (mds), or bone marrow stem cell disorder * subject has participated in any study evaluating peg-rhumgdf, recombinant human thrombopoietin (rhutpo), or related platelet product * subject has a known hypersensitivity to any recombinant e coli-derived product * subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of screening * subject is of reproductive potential and is not using adequate contraceptive precautions, in the judgment of the investigator * subject is pregnant or breast feeding * investigator has concerns regarding the subject's ability to comply with the protocol procedures

Keywords: platelet amg 531 thrombopoietin blood disorder bleeding disorder immune thrombocytopenic purpura idiopathic thrombocytopenic purpura immune (idiopathic) thrombocytopenic purpura tpo thrombopoietic protein
clinical evaluation of "snow-plow"technique versus bulk fill technique in restorations of class ii cavities

Conditions: Class II Dental Caries

Summary: the aim of the study is to assess the performance of " snow-plow" technique as compared to bulk fill technique in restoration of class ii cavities.

1. with limited evidence-based information about the clinical performance of resin composite in class ii cavities. it is beneficial to compare the newly introduced "snow-plow' technique using a randomized clinical trial to test the null hypothesis that this new technique has the same clinical performance. 2. the comparator will be the bulk fill technique as an alternative to the conventional layering technique. this is because it has shown lower polymerization shrinkage when comparing it to the conventional composite. bulk fill has reduced the chair time for the patient. it is done by the application of 4mm increment and cured at once. 3. patients are selected according to the eligibility criteria discussed in the following section. 4. local anesthesia will be administered and the operative field will be isolated before starting the restorative procedure. a standard class ii cavity will be prepared at the two-surface cavities. 5. the preparation will be performed using rotary instrumentation for cavity preparation by a water-cooled high-speed hand-piece by the same operator. 6. the teeth are then restored using one of the two techniques according to their allocation with the same steps discussed in the different arms. 7. the restorations are assessed using the modified usphs criteria at the time intervals stated in the outcome measures.

Eligibility criteria:
inclusion criteria: * class ii carious lesions in premolars and molars. * vital upper or lower teeth with no signs of irreversible pulpitis. * presence of favorable occlusion and teeth are in normal contact with the adjacent teeth. exclusion criteria: * deep carious defects (close to pulp, less than 1 mm distance). * periapical pathology or signs of pulpal pathology. * endodontically treated teeth * tooth hypersensitivity. * possible prosthodontic restoration of teeth. * heavy occlusion or occlusal contacts or history of bruxism. * severe periodontal affection.
serum, plasma, dna and tissue bank in chronic obstructive pulmonary disease and lung cancer

Conditions: Chronic Obstructive Pulmonary Disease; Lung Cancer

Summary: a biobank of serum, plasma, dna samples together with clinical information including specific questionnaires, complete pulmonary function and chest ct-scan, is prospectively collected in patients seen at the investigators' clinical service. the objective is to study candidate gene pathways in copd and or lung cancer and to associate them with the clinical characteristics and phenotypes of copd/emphysema and lung cancer. in subgroups of well characterised patients, other biological materials are also collected (lung tissue biopsies, peripheral blood mononuclear cells).

all patients with a smoking history of at least 15 pack years, an minimal age of 50 years and an recent available ct scan are enrolled. all subjects with a diagnosis of lung cancer are also collected (irrespective of age and smoking behavior). in addition the investigators collect: * specific questionnaires (mrc, ccq and smoking history) * medical and professional history * complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity) * serum, plasma and dna samples. in specific subgroups the investigators also collect: * peripheral blood mononuclear cells * lung tissue - if available - from a surgical procedure (lung transplantation or lobectomy)

Eligibility criteria:
inclusion criteria for smokers: * a smoking history of at least 15 pack years and age of 50 years or older * complete pulmonary function on day of visit * chest ct-scan within one year of enrollment * 4 weeks from exacerbation exclusion criteria for smokers: * less than 15 pack years * younger than 50 year * other pulmonary diseases interfering with ct or pulmonary function * asthma inclusion criteria for lung cancer patients: * new diagnosis of proven lung cancer * chest ct scan within 2 months of enrollment * complete pulmonary function exclusion criteria for lung cancer patients * not able to perform pulmonary function * absence of histological diagnosis of lung cancer

Keywords: copd lung cancer genes dna
dissonance inpatient relapse prevention program for anorexia nervosa

Conditions: Anorexia Nervosa

Summary: anorexia nervosa inpatient treatment has often a short-term success as weight is restored to a healthy level, but high percentage of patients relapse during the first year following the discharge. the development of strategies to overcome this problem represents a priority for clinicians. aim of this trial is to evaluate the effects of a relapse prevention program based on cognitive dissonance theory developed for hospitalized patients.

inpatient treatment for anorexia nervosa is often successful in restoring body weight, but a high percentage of patients relapse following discharge. the aim of the study was to assess the effect of a relapse prevention program during the last phase of inpatient treatment. patients, when they achieve a bmi of 18.5, are randomly allocated to complete the standard cognitive behavior inpatient treatment (cbt-i) or to complete the standard cbt-i plus eight relapse prevention groups based on the cognitive dissonance. the intervention has been derived by the selective and indicated prevention programs using a dissonance-based approach. this intervention showed to be effective in reducing the risk for eating pathology onset. the primary outcome of the study is to assess the number of patients allocated to the two condition with a bmi equal or greater than 18.5 at 12-months after discharge.

Eligibility criteria:
inclusion criteria: * female * body mass index ≥ 18.5 * anorexia nervosa patients admitted to inpatient treatment * written informed consent exclusion criteria: * male * schizophrenia or other psychiatric disorders * substance abuse * medical complication that may hamper the interpretation of results (medical condition that causes weight changes) * absence of medical treatment (drugs) that may hamper the interpretation of results * pregnancy or plan to get pregnant

Keywords: anorexia nervosa relapse prevention cognitive dissonance inpatient treatment cognitive behavior therapy